Placebo-Contolled, Double-Blind, Phase 2a Study to Evaluate the Safety, Efficacy of Orally Administered AMT-101 in Subjects with Moderate to Severe Active UC
- AMT-101 is orally administered
- Males and females 18-80 with a diagnosis of moderately to severely active UC.
- Cannot have failed or had inadequate response to both biologic and Tofacitnib for UC
- Can be on stable doses of 5-ASA, Steroids, 6-MP, AZA and MTX
If you are interested in participating in clinical studies, please send an email to email@example.com.